CAMK2N1 and ductal breast carcinoma in situ: CAMK2N1 itself has been reported as a prognostic marker for ovarian cancer45 and expression of which plays a tumour suppressive role in prostate cancer46 and glioma47, and in comparing all Pure DCIS with all other DCIS samples, is significantly down regulated in Not Pure DCIS samples (Fig. 6b).